BioReference LABORATORI ES Sr OFVCCIHealth Company FINAL REPORT

BioReference LABORATORI ES Sr OFVCCIHealth Company FINAL REPORT INores: 1. rPsTEIN, 7EFFREY D08: 81/28/1953 Age: 64 y Sex: m U/FL: Bed: Rm: Patient ED: Address:9 EAST 715T STREET, NEW YORK, MY 10021 11: NCN FASTING S A 0 Specimen IR: 104659439 Date Of Report: 89/21/2017 10:08 Date Collected: 09/15/2017 08:57 Date Received: 09/15/2017 23:06 North America Eastern Ttnie NOTE: SST tube submitted was inadequately spun. Serum was found to contain RBCs. Certain tests, e.g. Glucose, may be decreased while others e.g. Potassium or LOH may be elevated. CLINICAL REPORT Clinical Abnormalities Summary: rmay not contain all abnormal results; narrative results may not have abnormal flags. Please review entire report.) Cholesterol 224 HI Triglycerides 646 HI ROL CHOL., DIRECT 29 LO HDL as % of 13 • Choi/HDL Ratio 7.7 • NON-HDL 195 HI Cholesterol CHOLESTEROL HEP. A Ab., TOTAL Reactive * HEP. H SURF. AR. Reactive • 250H, VITAMIN D 31.5 LO PTH(3), INTACT 196.9 HI PNEUMO Ab TYPE 1 0.3 LO PNEUMO Ab TYPE 4 8.8 LO (58) (58) PNEUMO Ab TYPE 8 0.6 LO PNEUMO Ab TYPE 9 (9N) 8.7 LO PNEUMO Ab TVPE 12 (12F) (58) (58) (58) PNEUMO Ab TYPE 19 (19F) 1.1 LO PNEUMO Ab TYPE 23 (23F) 0.3 LD PRELIM° Ab TYPE 26 (68) 8.9 LO (58) (58) (58) PNEUMO Ab TYPE 68 (9V) 9.5 LO B.Henselae IgG Ab 1:64 • (58) (3) Albumin 4.7 9.8 3.5.5.2 8.6-12.4 g/dL Ing/ill• • 4.5 9.708/30/1017 30 -.Calcium -* CARDIOVASCULAR/LIPIDS *-- 224HI <200 mg/dL 226 HI 8/30/2017 cholesterol Triglycerides BBL 0440L'eroEcr .646 MI 29 LO <Ise >40 :mg/dL mg/a IS29 Mt TNP 8E/80/2017 08/39iidij . HDL es t.0 Choles —11-1--- >14 yNp 08/30/2017 Evaluation: ABOVE AVG.(OWDERATE RISK) Ratio 7.7 a <7.4 • Evaluation: ABM AVO.(MODERATE RISK) to HDL Ratio 7.-- -comet:MR - i98 MI 4136 mg/dL ELbranCeitiirer <lee 44041:.uoioto to coiculate.m. due to a Triglycerido level of greater tton 408 Ii/dL. ,•-• •. VLDL, CALCULATED Can't Calm 7-32 mg/di Aa, avaiiiiii7 tote-ot/30/2e0 esini2015 • • " (._.Can't CaLc 108/39/2017 ...._.... •-- BioReference Laboratories, Inc. 481 Edward H. Ross Dr I Elammod Park, NO B7407 I James Weisberger M.D. Page 1 of Laboratory Director 'rioted i,9/22/2917 89:57 EFTA00299765 BioReference LABoRAToRi Es an OPKO Health Company FINAL REPORT U ORSHER, STUART C3870 - STUART ORSHER, N.D. 9 EAST 79TM 5T, NEW YORK, NY 10021 Acct #: (C3070) P: MO CLINICAL REPORT EPSTEIN, JEFFREY DOB: 01/20/1953 Age: 64 y Sex: m U/FL: Bed: Na: Patient ID: Address:9 EAST 71ST STREET, NEW YORK, HY 10021 Can't Calc: One or more components was outside the measurable range. We are unable to calculate. a p E Specimen ID: 104659439 Date Of Report: 09/21/2017 10:88 Date Collected: 09/15/2017 88:57 Date Received: 09/15/2017 23:06 North Americo Eastern Time --* MISCELLANEOUS T5H 1.770 0.178-4.530 uIU/aIL TNP 08/30/2017 7.3 4.9-12.9 ug/dL TNP 08/30/2017 ill UPTAKE (13U) 31.0 24.3-39.0 TNP 08/30/2017 rffirmodat, FREE (aT4Y • 3.11 —6710--1.71r ng/d1 TNP 08/30/2017 • :FREE T4 INDEX 2.3 1.5-3.8 . . TNP 98/30/2017 --14NP 1T3 (THYRONINE), TOTAL -IgM 127 -180 r&dL B/30/1017 • HEP: A Ab:,. Non- Non-Reactive .••.• Reactive NOTE: Hep A Ab,IgM is positive or reactive during the acute phase. Hep A Ab/Total is positive or reactive during the recovery phase or is indicative of a past infection. - Non-Reactive ;MEP. B CORE Ab. I66 • Non-Reactive B SURF. A4 • NEP. IT-417' BE AO.- WTOSTERDNE; TOT.,S: Non- Reactive Ramage • Na7kaaifive TNP TAP.88/30/2017 08/30/2017 tioh- Reactive Negative legative Negative • Negative • 194.3 Non-Reactive 193.44463 ---- NOTE: Patients receiving the drug Nandrolone cannot be tested for TESTOSTERONE, total using the EIA method (test code 0379-8) due to a strong interference from the drug. Clinicians are asked to request Testosterone, Total by LC/H5/MS (test code )4516) for these Patients. gii Nakk.RiN15. 0..6e. 14 10-57 nmol/L ' tl.e4 30.00-150.00 pg/mL LH 3.8 1.74.6 mIU/mi Ci 280 s€t BELOW 39-308 Q/L ill QUINTANA AB 6/N (30 ' B. quintana Ab, IgM . < 2:16 --INTERPRETIVE INFORMAT/ON: Bartonella Quintana Ab, lgm -- Less than 1:16 Negative -No significant level of ..... . TNP BB/30/291 7 eaftifidi7 • 88/30/2017 08/30/2017 018/10/1017 08/362017 BioReference Laboratories, Inc. 481 Edward R. Ross Dr I Elmwood Park. NJ 07407 t James Weisberger M.D. Page 2 of 5 Laboratory Director Printed 09/22/2017 09:57 EFTA00299766 13ioReference LASORATOR/ES an OPKO Health Company FINAL REPORT ORSHER, STUART C3070 - STUART ORSHER, M.O. 9 EAST 79TH 57, NEW YORK, NY 10021 Acct a: (C3070) P. EPSTEIN, JEFFREY DOB: 01/20/1953 Age: 64 y Sex: H U/FL: Bed: Rm: Patient ID: Address:9 EAST 71ST STREET, NEW YORK, NY 10821 Bartonel a quintana IgN antibody detected. 1:16 or greater Positive -Presence of IgM antibody to Bartonella quintana detected, suggestive of current or recent infection. --The presence of 1.0( antibodies suggests recent infection. Low --levels of IgM antibodies may occasionally persist for more than 12 . --months post-infection. --Test developed and characteristics determined by ARUP --Laboratories. See Compliance Statement A: aruplab.com/CS --www.aruplab.com, Julio Delgado, MD - Lab. Director B. quintana Ab, Ig6 <1:64 --INTERPRETIVE INFORMATION: ilartonella quintana Antibody, IgG -- Less than 1:64 Negative: No significant level of Bartonella quintana Ig6 antibody detected. 1:64 - 1:128 Equivocal: Questionable presence of Bartonella quintana Ig6 antibody detected. Repeat testing in 20-14 days may be helpful. 1:256 or greater Positive: Presence of IgG antibody to Bartonella quintana detected, suggestive of current or past infection. --A low positive suggests past exposure or infection, while high --positivB reSUltS may indicate recent or current infection, but is --inconclusive for diagnosis. Seroconversion between acute and --convalescent sera is considered strong evidence of recent --infection. The best evidence for infection is a significant change --on two .appropriately timed specimens where both tests are done in --the same laboratory at the same time. --Test developed and characteristics determined by AK, i --Laboratories. See Compliance Statement A: aruplab.con/CS 'HEP. C Ab. Non-Reactive Non- Reactive NEPCAML*(5CCORAne 0.03 (314 : performed .by: Master •atessamilmit 0.80 fIRU7. SOO Chipeta Way. Salt Lake City, UT 841011 Hepatitis 8 Result Interpretation (for reference. use only) il/EAs Acute Oast Chronic IMV eat + t - .t S A p L Specimen ID: 104659439 Date Of Report: 89/21/2017 10:08 Date Collected:09/15/2817 88:57 ate Received: 09/15/2017 23:06 North Americo Eastern Time VIP IMP . • 08/30/2017 SioReference Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park, N3 07487 JainesWelabargeril.D. Page 3 of 5 Laborator/Director Printed 09/22/2917 09:57 EFTA00299767 BioReference LABORATOR IES an OPKOHealth Company FINAL REPORT D a r. mom, STUART C3070 - STUART ORSHER, N.D. 9 EAST 791N ST, EA YORK, NY 10021 cct 8: (C3070) P: MO mBeAg HEP.B.CORE AB,IgM HEP.B.CORE AB. N8eAb MBSAb "Late Incubation/Early Acute IIIe:EPSTEIN, 7EFFREY DOB: 01/20/1963 Age: 64 V Sex: e U/FL: Patient ID: Bed: R Address:9 EAST 11ST STREET, NEW NUFK, Pe 10821 +/- +/- P: I . NOTE: In remote past infection, HBsAb level may be Negative or Mon-Reactive in Some patients. ACID 7.77 : Folic Acid Range Weal Borderline deficient Deficient EXCe8Sive 1:14114exitil 359 ,2SON, VITAMIN 0 VITAMIN 0,25-0H TEST INFORMATION Range (ng/mL) <20.8 20.0-31.9 32.0-100.0 >100.0 + - + +/. >5.38 ng/oL Units (ng/eL) >5.38 3.38-5.38 0.35-3.37 >24.00 Specimen ID: 18404430 Date Of Report: 09/21/2017 10:08 ate Collected: 09/15/2017 08:57 Date Received: 40/13/2017 23:06 Atrit, AmPrica fs5terr tep 040/241i niaar Tip-• - "." 'heir ' '" Suggested Interpretation Deficient Insufficient Sufficient Possible Adverse Effects Tgrolasobwo0dict . 52.8 ' ..... IPTH(3), INTACT 106.0 HI :PERM Ablwq 1 (58) 0.3 LO ANEUMO Ab TYPE 3 (58).1.---__,,-,__...... 1.8 mum AD TYPE nal .. 0.8 LO PRES Ab TYPE 8 (58) 0.6 tO iani—Thi firi 9 (48) (se) POOSo -An DOELi -(11O) (41)"' NEUMD Ab TYPE 14 0107---' >it.3 TPNEUNO Ab TYPE 19 (19F) (58) ' WOW-a TYPE 10 (20)(037 — pwuko Ab TYPE 26 (GB) (58) iiPECIMO Ab TYPE 5 8.i--- pili(446 6 WOE if (10j .(34)- —I:4 • -0140413743T*E -T6 - titC71413 -1.8 • • meupb At; TYPE 66 (9w) (51).ii7iciic5 -----'-iiiii7 I....n.77 1WW-- 14/31755ii - i3.1:44.8 -. nenL "-- 71143 0/36/2817-, 51.3 . ug/fiL (0.3 D 08/30/2017 >1.3 ' ' Ug/iL 1.4 08/3e/2017 cCI-- . Ug/IL .. 9.6 L BB/38/ 8i7 >2.3 Ug/mi -. ' 4:4 LO ' 08/30/24317 0.7 LO >4.1 ' • UgieL: /30/2817 - 4.1 L0 >1:3 ' -6024L. 08/30/2017 >1.3 Wet 23.2 08 30/1017 1.1 L0 ii:i -. ueini - 9.8 to 00/30/2017 Ira >1.3 . 4717 -8 i t'0.3 LO Os/ /2817 8.4 LO )1.3 wi/wL ti.s tO 08/3e/2017 - >1.3 48/71C . ......... ...'≥LS' ug/iL 1.5 08/30/2017 >1.3 80/0 • I.3 0--- beWeifrozl. 0.0 Lo ..i1:3 - ug/nL 4:4 io 08/30/2017 • *This test was developed and its performance characteristics determined by ......_ bloaelerence Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park, 83 07407 Page 4 of 5 JanemONebelmwDereeD. Laboratory okootor Printed 49/22/2027 09:57 EFTA00299768 Bio Reference FINAL REPORT sORATORIEs en Orlin" Health Company WISNER, STUART [3070 - STUART ORSHER, M.D. (EPSTEIN, 3EFFREY DOD: 01/20/1953 Age: 64 Y Ser: M Red: S A Specimen ID: 104659439 Date Of Report: 09/21/2017 10:08 Date Collected: 09/15/2817 04:S7 Date Received: 09/15/2017 23:0S 9 EAST 79TH ST, Patient ID: 0 NEW YORK, NY 184321 Address: 9 EAST 71ST STREET, Acct #: (C3078) MD P: NEN YORK, NY 10821 P: E North America Eastern Tier CLINICAL REPORT " • . 4.-4,:•••••• •• • ••••••It • i• "41.1 • '•• ••• ••'• .•'•• • " I Viracor EurofinS. It as no, teen clear? or . Drug Administration. Testing Performed At: Viracor Eurofins 1001 NW Technology Drive . Lee's Summit, MO 64886 IIIMMESICLIM 643 e.11eitflfliekid Ab (3) piiieriieile l`gM Ab (3) <1:20 aPPrOve 1:64 • •ie •••• • -••• • <1:20 08/30/2017'08/30/aiii'l. • titer 1:64 g titer This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Valencia. It has not been cleared or approved by the US Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. (3) Performed by: Quest Diagnostics Nichols Institute of Valencia 27027 Tourney Road Valencia, CA 9135S-5386 (S8) Performed by: viracor Eurofins Clinical Diagnostic 1001 NW Technology brive Lees Summit, MO 64086 NOTE: Specimen submitted is LIPEMIC. This may cause inaccurate rnsults. Please resubmit a fasting specimen at your earliest convenience. SioReference laboratories, Inc. 481 Edward R. Ross Or I Elmwood Park, NJ 07407 l James Weisberger M.D. Page 5 of S LaboretopylDkeclor Printed 09/22/2017 09:57 EFTA00299769